Markedly improved disease control in Darier disease ( ATP2A2 -nonsyndromic epidermal differentiation disorder) with ustekinumab versus other biologics: a case series
Skin Health and Disease · 31.07.2026 · 6 (4) · 593-599
DOI: 10.1093/skinhd/vzag072 ↗Kurz gefasst
Fallbericht in der Zeitschrift Skin Health and Disease, online erschienen am 23.06.2026. Verfasst von Anna Skarnvad Andersen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In this case series, we report six patients with severe, treatment-refractory Darier disease, or dyskeratosis follicularis, also known as ATP2A2-nEDD (nonsyndromic epidermal differentiation disorder), treated with off-label biologic therapy, including dupilumab (n = 3), secukinumab followed by guselkumab (n = 1), and ustekinumab (n = 2). All patients had longstanding disease with recurrent flares, frequent infections and substantial impairment of quality of life, despite multiple conventional treatments. All biologic treatments were well tolerated, with no serious adverse events. Dupilumab consistently improved pruritus but had limited effects on skin lesions. Secukinumab and guselkumab provided only transient or partial disease control. In contrast, both patients treated with ustekinumab achieved pronounced and sustained clinical improvement, with markedly reduced disease severity and pruritus, and considerable improved quality of life. The pronounced and sustained responses observed with ustekinumab support its prioritization for future studies in Darier disease.
Autor:innen und Institutionen
- Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Anna Skarnvad Andersen
Zitieren
APA
Skarnvad Andersen, A., Baez, E., Emmanuel, T., Rønholt, K., Sommerlund, M., & Johansen, C. (2026). Markedly improved disease control in Darier disease ( ATP2A2 -nonsyndromic epidermal differentiation disorder) with ustekinumab versus other biologics: a case series. Skin Health and Disease, 6(4), 593-599. https://doi.org/10.1093/skinhd/vzag072
Vancouver
Skarnvad Andersen A, Baez E, Emmanuel T, Rønholt K, Sommerlund M, Johansen C. Markedly improved disease control in Darier disease ( ATP2A2 -nonsyndromic epidermal differentiation disorder) with ustekinumab versus other biologics: a case series. Skin Health and Disease. 2026;6(4):593-599. doi:10.1093/skinhd/vzag072
BibTeX
@article{SkarnvadAndersen2026,
author = {Skarnvad Andersen, Anna and Baez, Elena and Emmanuel, Thomas and Rønholt, Kirsten and Sommerlund, Mette and Johansen, Claus},
title = {Markedly improved disease control in Darier disease ( ATP2A2 -nonsyndromic epidermal differentiation disorder) with ustekinumab versus other biologics: a case series},
journal = {Skin Health and Disease},
year = {2026},
volume = {6},
number = {4},
pages = {593--599},
doi = {10.1093/skinhd/vzag072}
}
EUVIMED